[go: up one dir, main page]

AR127559A1 - COMPOUNDS, COMPOSITIONS AND METHODS - Google Patents

COMPOUNDS, COMPOSITIONS AND METHODS

Info

Publication number
AR127559A1
AR127559A1 ARP220103009A ARP220103009A AR127559A1 AR 127559 A1 AR127559 A1 AR 127559A1 AR P220103009 A ARP220103009 A AR P220103009A AR P220103009 A ARP220103009 A AR P220103009A AR 127559 A1 AR127559 A1 AR 127559A1
Authority
AR
Argentina
Prior art keywords
compositions
compounds
methods
compound
pharmaceutically acceptable
Prior art date
Application number
ARP220103009A
Other languages
Spanish (es)
Inventor
Anjali Pandey
Biswajit Kalita
Athisayamani Jeyaraj Duraiswamy
Original Assignee
Aria Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aria Pharmaceuticals Inc filed Critical Aria Pharmaceuticals Inc
Publication of AR127559A1 publication Critical patent/AR127559A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un compuesto de la fórmula (1). Reivindicación 35: Una composición farmacéutica que comprende un compuesto de cualquier reivindicación anterior, o una sal farmacéuticamente aceptable, estereoisómero, mezcla de estereoisómeros o profármaco de este, y un portador farmacéuticamente aceptable.A compound of the formula (1). Claim 35: A pharmaceutical composition comprising a compound of any preceding claim, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and a pharmaceutically acceptable carrier.

ARP220103009A 2021-11-02 2022-11-02 COMPOUNDS, COMPOSITIONS AND METHODS AR127559A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163274916P 2021-11-02 2021-11-02

Publications (1)

Publication Number Publication Date
AR127559A1 true AR127559A1 (en) 2024-02-07

Family

ID=84364211

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103009A AR127559A1 (en) 2021-11-02 2022-11-02 COMPOUNDS, COMPOSITIONS AND METHODS

Country Status (3)

Country Link
AR (1) AR127559A1 (en)
TW (1) TW202334135A (en)
WO (1) WO2023081666A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2499465A1 (en) * 2002-07-16 2004-01-22 Amura Therapeutics Limited Biologically active compounds
EP1565436B1 (en) * 2002-11-27 2012-04-25 Incyte Corporation 3-aminopyrrolidine derivatives as modulators of chemokine receptors
WO2012125661A1 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Substituted 3-azabicyclo[3.1.0]hexane derivatives useful as ccr2 antagonists

Also Published As

Publication number Publication date
TW202334135A (en) 2023-09-01
WO2023081666A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
ECSP20044709A (en) CARDIAC SARCOMER INHIBITORS
ZA202200519B (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
MX2022004451A (en) HETEROARYL-BIPHENYL-AMIDES FOR THE TREATMENT OF DISEASES RELATED TO THE PD-L1 LIGAND.
AR056873A1 (en) DERIVATIVES OF PIRAZOLOPIRIMIDINAS AS QUINASA INHIBITORS OF CYCLINE DEPENDENTS, PHARMACEUTICAL COMPOSITIONS
MX2025004220A (en) Tricyclic compounds and their uses
MX2024009926A (en) Compositions and methods for treating cns disorders.
MX2020009530A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors.
MX2024003738A (en) Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds.
MX2022004450A (en) HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES.
DOP2024000146A (en) PARP7 INHIBITORS
WO2022104153A3 (en) Compounds and methods for treating viral infections
MX2024012470A (en) Cdk9 inhibitors
MX2021003232A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors.
CO2022008616A2 (en) Oral pharmaceutical composition comprising carbamate compound and method of preparation therefor
EA202192530A1 (en) COMPOUNDS, COMPOSITIONS AND METHODS
AR127496A1 (en) CD73 COMPOUNDS
CR20230218A (en) New indazole acetylene derivatives
AR127559A1 (en) COMPOUNDS, COMPOSITIONS AND METHODS
AR133240A1 (en) COMPOUNDS, COMPOSITIONS AND METHODS
AR132818A1 (en) COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE
AR133241A1 (en) COMPOUNDS, COMPOSITIONS AND METHODS
MX2022005199A (en) SSAO INHIBITORS AND USE THEREOF.
WO2020251871A3 (en) Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
MX2024008745A (en) COMPOUND DERIVED FROM 1,3-BENZODIOXOL AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT.
AR130303A1 (en) PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE

Legal Events

Date Code Title Description
FB Suspension of granting procedure